Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. [electronic resource]
Producer: 20160225Description: 335-40 p. digitalISSN:- 2152-2669
- Administration, Intravenous
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Busulfan -- administration & dosage
- Disease-Free Survival
- Drug Therapy, Combination
- Female
- Graft vs Host Disease -- prevention & control
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Immunosuppressive Agents -- therapeutic use
- Lymphoma, Non-Hodgkin -- mortality
- Male
- Methotrexate -- therapeutic use
- Middle Aged
- Myeloablative Agonists -- administration & dosage
- Recurrence
- Retrospective Studies
- Survival Rate
- Tacrolimus -- therapeutic use
- Transplantation Conditioning -- methods
- Transplantation, Homologous
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.